Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine
| Autor: | Yuling Wu, Shifu Chen, Jiajia Zhang, Jikui Liu, Jingxian Duan, Tieshan Feng, Zhicheng Li, Zhichao Fu, Ming Liu, Jie Han |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.diagnostic_test
business.industry Melanoma medicine.disease Precision medicine Immune checkpoint 03 medical and health sciences 0302 clinical medicine Genetic marker 030220 oncology & carcinogenesis Hepatocellular carcinoma Cancer research Medicine 030211 gastroenterology & hepatology Epigenetics business Lung cancer Genetic testing |
| Zdroj: | Journal of Hepatocellular Carcinoma. 6:151-166 |
| ISSN: | 2253-5969 |
| DOI: | 10.2147/jhc.s224849 |
| Popis: | Being one of the most lethal cancers that exhibit high levels of heterogeneity, hepatocellular carcinoma (HCC) is associated with diverse oncogenic pathways underpinned by varied driver genes. HCC can be induced by different etiological factors including virus infection, toxin exposure or metabolic disorders. Consequently, patients may display varied genetic profiles, and may respond differently to the treatments involving inhibition of target pathways. These DNA/RNA mutations, copy number variations, chromatin structural changes, aberrant expression of non-coding RNAs and epigenetic modifications were considered as biomarkers in the application of precision medication. To explore how genetic testing could contribute to early diagnosis, prognosis, treatment and postoperative monitoring of HCC, we conducted a systematic review of genetic markers associated with different pathologies. Moreover, we summarized on-going clinical trials for HCC treatment, including the trials for multiple kinase inhibitors and immune checkpoint blockade (ICB). The efficacy of ICB treatment in HCC is not as good as what was observed in lung cancer and melanoma, which might be due to the heterogeneity of the microenvironment of the liver. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|